![Stephen Hoge](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephen Hoge
President bij MODERNA, INC.
Vermogen: 87 M $ op 31-10-2024
Profiel
Momenteel bekleedt Stephen Hoge de functie van President bij Moderna, Inc. en President bij ModernaTX, Inc. (een dochteronderneming van Moderna, Inc.). Hij is tevens lid van de raad van bestuur van Axcella Health, Inc. en President voor ModernaTX, Inc. In zijn vorige loopbaan was hij partner bij McKinsey & Co, Inc. Hij behaalde zijn doctoraal aan het Amherst College en zijn doctoraat aan de Universiteit van Californië, San Francisco.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
MODERNA, INC.
0.42% | 29-11-2024 | 1 599 616 ( 0.42% ) | 87 M $ | 31-10-2024 |
Laatste nieuws over Stephen Hoge
Actieve functies van Stephen Hoge
| Bedrijven | Functie | Begin |
|---|---|---|
| MODERNA, INC. | President | 01-02-2015 |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | President | - |
Eerdere bekende functies van Stephen Hoge
| Bedrijven | Functie | Einde |
|---|---|---|
| AXCA HEALPAR | Directeur/Bestuurslid | 19-05-2022 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-12-2012 |
Opleiding van Stephen Hoge
| Amherst College | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MODERNA, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Axcella Health, Inc.
 Axcella Health, Inc. BiotechnologyHealth Technology Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
